These five high-yield dividend stocks with solid upside potential and Buy ratings make sense for growth and income investors ...

Okay, no, look, I’m a Eli Lilly guy, okay? I’m going to stick with it. If I’m going to do Viking, I’m going to do Viking ...

Jim Cramer, the host of Mad Money, said on Thursday that the market is moving through a familiar rotation in which stocks ...

On paper, Ireland is richer than Singapore—and both are richer than the United States, Switzerland, and every country in the ...

From who owns the San Francisco 49ers to when they play next. Here's what to know about the five time Super Bowl championship ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Procter & Gamble has given its new CEO, Shailesh Jejurikar, a powerful performance incentive to improve the company’s results ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

Diversification is key to successful long-term investing. In other words, don't put all your eggs in one basket.